Larch Arabinogalactan for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Larch Arabinogalactan for Health & Longevity

Created on 09/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A soluble larch-wood fiber, cleared for food use. Best-supported effect: a sharper antibody response to bacterial vaccine material, and fewer colds in adults who catch them often, though first-day symptoms were rated worse. Gut bacteria shift, including an unwelcome drop in variety. Cholesterol and blood sugar claims were tested; nothing was found. Inexpensive, well tolerated; immune trials were manufacturer-funded. (Full Review)

Protocol

Immune-oriented dose
4.5 g daily
Purified powder; the dose at which effects have been most consistent across studies.
Digestive-oriented dose
15 g daily
Targets fermentation, not immune priming; intakes at this level are split into two or three portions with meals.
Loading period before challenge
30 days ahead
Both vaccine trials began supplementation 30 days before vaccination.
Time to effect
Vaccine antibody response
30 days
Loading required before challenge.
Cold incidence
12 weeks
Interval over which the effect was measured.
Microbiota & stool chemistry
3–6 weeks
Changes appear within this window.

Benefits

Contraindications
  • Known allergy to larch, conifer wood dust or larch-derived food additives
  • Solid-organ transplant recipients (particularly within 12 months of transplantation)
  • Active severe inflammatory bowel disease flare (including acute severe ulcerative colitis requiring hospitalisation)
  • Confirmed small intestinal bacterial overgrowth until treated and retested
  • Classical galactosaemia
  • Pregnancy and lactation (absence of data rather than evidence of harm)
    •
Key Interactions
  • Narrow-therapeutic-index oral medications (levothyroxine, digoxin, warfarin)
  • Immunosuppressants (tacrolimus, ciclosporin, mycophenolate, prednisone)
  • Systemic antibiotics (amoxicillin, azithromycin, ciprofloxacin)
  • Oral laxatives and bulking agents (psyllium, methylcellulose, lactulose, polyethylene glycol)
  • Other prebiotic supplements (inulin, fructo-oligosaccharides, galacto-oligosaccharides, partially hydrolysed guar gum)
  • Immune-stimulating supplements (echinacea, beta-glucans, elderberry, colostrum)
  • Probiotic supplements (Lactobacillus, Bifidobacterium strains)
  • Other interventions (low-FODMAP diet, colonoscopy bowel preparation)
    •

Risk & Side Effects

  • High: Gastrointestinal gas, bloating and fermentation discomfort
    •
  • Medium: More intense symptoms at the onset of a cold
    •
  • Low:
  • Speculative: Reduced fecal bacterial diversity; hypersensitivity and anaphylactoid reactions; unwanted immune activation in autoimmunity or transplantation

Monitoring

Marker Target Why
hs-CRP Below 1.0 mg/L Detects any shift in background inflammatory tone.
Complete blood count with differential White cells 4.0–7.0 × 109/L; lymphocytes 20–40% Tracks the immune-cell compartment the compound is claimed to influence.
Fasting lipid panel Triglycerides below 80 mg/dL; HDL above 55 mg/dL Tests the widely claimed but unconfirmed cholesterol benefit against the individual's own baseline.
HbA1c 4.8–5.4% Detects any change in glucose control from altered fermentation.
Comprehensive metabolic panel Within laboratory reference range Confirms absence of liver or kidney effect during prolonged use.
Fecal calprotectin Below 50 µg/g Flags mucosal inflammation that fermentable substrate could aggravate.
Stool bacterial composition No established target; track change from own baseline in Bifidobacterium and Bacteroides abundance Shows whether the fermentation mechanism is engaging at all.

Cadence: Baseline panel before starting, repeated at 12 weeks, then at 6 and 12 months if use continues; symptom and infection diaries kept continuously throughout.

Qualitative Assessment

  • Number and duration of upper-respiratory infection episodes, recorded in a dated diary
  • Severity of symptoms on the first day of an episode, given the finding of more intense early symptoms
  • Abdominal distension, flatulence and audible gut activity, rated daily during the titration period
  • Stool consistency and frequency, using a standard stool form scale
  • Energy levels and post-meal comfort, particularly in the two hours following a dose
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.